相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Michael Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation
Wengang Cao et al.
WORLD JOURNAL OF UROLOGY (2008)
A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150
A. Belch et al.
ANNALS OF ONCOLOGY (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma
Apollina Goel et al.
BLOOD (2006)
Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity
SJ Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism
F Pajonk et al.
BMC CANCER (2005)
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis
A Goel et al.
EXPERIMENTAL HEMATOLOGY (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells
JF Kurland et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition
F Pajonk et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
分享论文
